Hualan Biotech announced that Hualan Vaccine, a holding subsidiary of the company, has received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration. The novel influenza virus mRNA vaccine it declared met the drug registration requirements and agreed to carry out clinical trials. Hualan Vaccine is the first company in China to obtain implied approval for clinical trials of this vaccine. Currently, the vaccine still needs to carry out clinical trials, production declarations, and batch issuance, and there is uncertainty about subsequent progress and results.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.